Reto Ritschard
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Tumor-Infiltrating Lymphocyte Adoptive Cell Therapy With PD-1 Blockade in Pediatric Chemotherapy-Resistant Osteosarcoma.
Journal: Pediatric blood & cancer
Published: October 24, 2025
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma.
Journal: Immuno-oncology technology
Published: January 13, 2025
Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors.
Journal: Cancer immunology research
Published: October 23, 2024
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes.
Journal: Cancer immunology research
Published: September 12, 2023
A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer.
Journal: Scientific reports
Published: October 04, 2022
Targeting immunoliposomes to EGFR-positive glioblastoma.
Journal: ESMO open
Published: September 05, 2021
Plinabulin, a Distinct Microtubule-Targeting Chemotherapy, Promotes M1-Like Macrophage Polarization and Anti-tumor Immunity.
Journal: Frontiers in oncology
Published: December 21, 2020
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13).
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 08, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 11, 2017
Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.
Simultaneous targeting of VEGF-receptors 2 and 3 with immunoliposomes enhances therapeutic efficacy.
Journal: Journal of drug targeting
Published: July 24, 2015
Large-scale manufacturing of GMP-compliant anti-EGFR targeted nanocarriers: production of doxorubicin-loaded anti-EGFR-immunoliposomes for a first-in-man clinical trial.
Journal: International journal of pharmaceutics
Published: January 07, 2015
Last Updated: 09/26/2026